Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Open accessThe DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.
Abstract
Numerous studies have now shown that the amyloid beta-protein (Abeta), the principal component of cerebral plaques in Alzheimer disease, rapidly and potently inhibits certain forms of synaptic plasticity. The amyloid (or Abeta) hypothesis proposes that the continuous disruption of normal synaptic physiology by Abeta contributes to the development of Alzheimer disease. However, there is little consensus about how Abeta mediates this inhibition at the molecular level. Using mouse primary hippocampal neurons, we observed that a brief treatment with cell-derived, soluble, human Abeta disrupted the activation of three kinases (Erk/MAPK, CaMKII, and the phosphatidylinositol 3-kinase-activated protein Akt/protein kinase B) that are required for long term potentiation, whereas two other kinases (protein kinase A and protein kinase C) were stimulated normally. An antagonist of the insulin receptor family of tyrosine kinases was found to mimic the pattern of Abeta-mediated kinase inhibition. We then found that soluble Abeta binds to the insulin receptor and interferes with its insulin-induced autophosphorylation. Taken together, these data demonstrate that physiologically relevant levels of naturally secreted Abeta interfere with insulin receptor function in hippocampal neurons and prevent the rapid activation of specific kinases required for long term potentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“If Akt is not phosphorylated, GSK3-β remains active [93] and is described as responsible for events related to AD pathology, including the hyperphosphorylation of Tau [94].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Self-citationDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Long-Term Potentiation and Memory
LYNCH, M. A. (2004) · Physiological Reviews · doi:10.1152/physrev.00014.2003 · Cited by 1,991
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
Self-citationShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Self-citationRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene
Montminy, M. R., & Bilezikjian, L. M. (1987) · Nature · doi:10.1038/328175a0 · Cited by 1,357
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Cited by
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
“Further, the cell-derived oligomers blocked a chemically induced form of LTP caused by stimulating dissociated mouse hippocampal neurons with picrotoxin and glycine in the absence of added magnesium (Townsend et al. 2007).”
BackgroundSelf-citationLi, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.012 · Cited by 972
“, 2005), or insulin receptors (Townsend et al., 2007), all of which could modulate NMDAR activity.”
Self-citationBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Li, S., Jin, M., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0203-11.2011 · Cited by 671
“…impairs ERK/CREB phosphorylation Our result that soluble A significantly inhibits ERK and CREB phosphorylation is consistent with a previous report (Townsend et al., 2007) that the inactivation of ERK/CREB signaling pathway by soluble A species secreted by cultured cells takes a few hours but can…”
ResultSelf-citationDe Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
“The attack on synapses inhibits long-term potentiation (LTP) (11, 13, 14), a classic paradigm for memory-related synaptic mechanisms.”
BackgroundResultInfluentialBrain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622
“Vice versa, A oligomers impair insulin action by binding to insulin receptors, thereby disrupting the signaling capacity and downregulating insulin receptors in the hippocampus (355, 403).”
BackgroundAmyloid oligomers: formation and toxicity of Aβ oligomers
Sakono, M., & Zako, T. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07568.x · Cited by 605
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
“Soluble Ab can disrupt brain insulin signaling by binding to the insulin receptor (318), suggesting interactions between T2DM, glucose metabolism in the brain, and AD pathology.”
BackgroundKamat, P. K., Kalani, A., Rai, S., Swarnkar, S., Tota, S., Nath, C., & Tyagi, N. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9053-6 · Cited by 500
“In fact, oligomeric Aβmediated LTP impairment is believed to involve a decrease in the activation of MAPK, CaMKII, and Akt/protein kinase B, but not protein kinases A and C [61, 62].”
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., De Felice, F. G., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 468
“As a consequence, insulin prevents the overall negative impact of AbOs on neurons [20, 79].”
BackgroundGSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
“Interestingly, Aβ interferes not only with insulin but also with Wnt signaling pathways (Townsend et al., 2007; Magdesian et al., 2008).”
Backgroundβ-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421
“It is possible that A 1-42 monomers facilitate the activation of IGF-1/insulin receptors by locally produced IGF-1 or, alternatively, that A monomers bind to IGF-1/insulin receptors, as already shown for A oligomers (Xie et al., 2002; Townsend et al., 2007).”
BackgroundMolecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
“Taken together, these data demonstrate that physiologically relevant levels of naturally secreted A interfere with IR function and prevent the rapid activation of specific kinases required for long-term potentiation [46].”
BackgroundChen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y.-D., Ma, T., Thompson, R. C., Zhao, Y., Smith, L., Gasparini, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807991106 · Cited by 390
“Furthermore, a specific inhibitory effect of soluble A on insulin signaling has also been reported (43, 44).”
BackgroundFerreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
“Of considerable interest are findings that AβOs impair neuronal insulin signaling (Townsend et al., 2007; Zhao et al., 2008; De Felice et al., 2009; Bomfim et al., 2012), providing an explanation at the molecular/cellular level for the connection between AD and diabetes revealed by…”
BackgroundGSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
“Keywords: Alzheimer’s disease, GSK3, tau In 1906, Alois Alzheimer described two aberrant components found in the brain of a demented patient after death: senile plaques and neurofibrillary tangles [1].”
BackgroundKim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Self-citationTramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
“The mechanism of neuroprotection by insulin appears to involve downregulation of neuronal AbO binding sites [50] and increased oligomer clearance [75], consequently preventing IR internalization and synapse loss [50,76,77].”
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 322
“Additionally, soluble Aβ oligomers were shown to interfere with IR function, probably due to a loss of these receptors at dendrites and their increased expression in the cell soma [285], despite no changes in absolute hippocampal neuronal IR levels [286].”
BackgroundAlzheimer's disease: synapses gone cold
Koffie, R. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-63 · Cited by 308
“MAPK, CaMKII and Akt/protein kinase B, but not protein kinases A and C [53,83,84].”
Synaptic changes in Alzheimer’s disease and its models
Pozueta, J., Lefort, R., & Shelanski, M. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 307
Dendritic Spine Loss and Synaptic Alterations in Alzheimer’s Disease
Knobloch, M., & Mansuy, I. M. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8018-z · Cited by 296
O' Neill, C. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.02.025 · Cited by 290
Shelat, P. B., Chalimoniuk, M., Wang, J., Strosznajder, J. B., Lee, J. C., Sun, A. Y., Simonyi, A., & Sun, G. Y. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05347.x · Cited by 283
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
“Specifically, Aβ was shown to act through diminishing insulin-induced autophosphorylation (Townsend et al., 2007).”
BackgroundMa, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262
“On one hand, Ab was shown to impair insulin-PI3K-AKT signaling [2,45–47] and insulin treatment was reported to improve cognitive function in patients with early AD [48], while on the other hand, AD transgenic mice with reduced insulin signaling were reported to be protected against cognitive decline [49].”
BackgroundDual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice
Zhang, C., Wan, X., Zheng, X., Shao, X., Liu, Q., Zhang, Q., & Qian, Y. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.063 · Cited by 262
“The formation of amyloid plaque is caused by the increasing production, accumulation and aggregation of the amyloid-b (Ab) peptide [9,10].”
BackgroundAmyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101020 · Cited by 247
“possibly, Aβ monomers may bind to IGF-1/insulin receptors, as already shown for Aβ oligomers [109,110].”
McNay, E. C., & Recknagel, A. K. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.005 · Cited by 229
Insulin Resistance in Alzheimer's Disease
Ferreira, L. S. S., Fernandes, C. S., Vieira, M. N. N., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 228
Zhang, X., Tian, Y., Zhang, C., Tian, X., Ross, A. W., Moir, R. D., Sun, H., Tanzi, R. E., Moore, A., & Ran, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505420112 · Cited by 225
Insulin, cognition, and dementia
Cholerton, B., Baker, L. D., & Craft, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.008 · Cited by 229
“Soluble Aβ binds to the insulin receptor and disrupts its signaling capacity and induction of long-term potentiation in mouse hippocampal slice preparations (Townsend et al., 2007).”
BackgroundModulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases
Pajares, M., Cuadrado, A., & Rojo, A. I. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.006 · Cited by 220
Insulin receptor signaling in the development of neuronal structure and function
Chiu, S.-L., & Cline, H. T. (2010) · Neural Development · doi:10.1186/1749-8104-5-7 · Cited by 217
“Furthermore, increasing evidence shows that Ab binds to the insulin receptor, decreases the relative amount of insulin receptor in the dendritic compartment, and causes neuronal oxidative stress and loss of spines [153,169-171].”
BackgroundFemminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
“The key hallmarks of AD and neurodegeneration were reversed or improved, including β-amyloid synthesis, plaque formation, inflammation in the brain, synaptic loss, and memory impairment [36].”
BackgroundAmyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons
Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Shimoda, M., Matsuoka, M., & Aiso, S. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.105 · Cited by 194
The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-Amyloid
Lee, H.-K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0777 · Cited by 185
“In two other reports, extracellular A oligomers (ADDL) caused losses in surface IR number and/or reductions in insulin-induced IR phosphorylation in neurons (Townsend et al., 2007; Zhao et al., 2008).”
BackgroundCalcium/calmodulin-dependent kinase II and Alzheimer’s disease
Ghosh, A., & Giese, K. P. (2015) · Molecular Brain · doi:10.1186/s13041-015-0166-2 · Cited by 205
“Moreover, treating hippocampal neurons with Aβ oligomers impairs αCaMKII activation [64, 66].”
BackgroundIn vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases
Diaz-Hernandez, J. I., Gomez-Villafuertes, R., León-Otegui, M., Hontecillas-Prieto, L., del Puerto, A., Trejo, J. L., Lucas, J. J., Garrido, J. J., Gualix, J., Miras-Portugal, M. T., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.040 · Cited by 201
Dziewczapolski, G., Glogowski, C. M., Masliah, E., & Heinemann, S. F. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6159-08.2009 · Cited by 198
A three-step model for the synaptic recruitment of AMPA receptors
Opazo, P., & Choquet, D. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.08.014 · Cited by 190
“Second, Aβ oligomers interfere with the NMDARdependent activation of both CaMKII and PI3K (but not PKA) which are essential for the activity-dependent trapping of AMPARs (Gu et al., 2009; Townsend et al., 2007; Zhao et al., 2004).”
Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
von Bernhardi, R., & Eugenín, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 190
“There is evidence that Ab can induce glutamate release from primary cortical neurons and, in turn, alter signaling cascades that are required for long-term potentiation (646).”
BackgroundGoure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“Human LilrB2 [163] Insulin receptor [164] Sigma 2 receptor [165]”
BackgroundJimenez, S., Torres, M., Vizuete, M., Sanchez-Varo, R., Sanchez-Mejias, E., Trujillo-Estrada, L., Carmona-Cuenca, I., Caballero, C., Ruano, D., Gutierrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 188
Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188
Self-citationBrambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kóňa, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., et al. (2012) · ACS Nano · doi:10.1021/nn300489k · Cited by 188
(2009) · The Cambridge Medical School · doi:10.1017/cbo9780511693632.005 · Cited by 178
Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood
Lee, S.-H., Zabolotny, J. M., Huang, H., Lee, H., & Kim, Y.-B. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.011 · Cited by 176
“In hippocampal neuron cultures, Ab causes loss of IR on dendrites and interferes with insulin receptor signaling and long term potentiation [88,113].”
BackgroundInflammation and NF-κB in Alzheimer's Disease and Diabetes
Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G., & Eisel, U. L. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0976 · Cited by 173
“The binding of these ligands to their respective receptors, i.e., the TNF-R, Toll-like receptor (TLR) and the interleukin-1 receptor (IL-1R) superfamilies, causes activation of various cellular signaling pathways such as the protein kinase C (PKC), mitogen-activatedprotein (MAP) kinase kinase kinase-1 (MEKK1), and als…”
InfluentialType 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach
Cholerton, B., Baker, L. D., Montine, T. J., & Craft, S. (2016) · Diabetes Spectrum · doi:10.2337/ds16-0041 · Cited by 170
GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration
Salcedo-Tello, P., Ortiz-Matamoros, A., & Arias, C. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189728 · Cited by 166
“In turn, the absence of activated Akt prevents the inhibitory phosphorylation of GSK3, increasing its activity [144].”
BackgroundGao, C., Hölscher, C., Liu, Y., & Li, L. (2012) · revneuro · doi:10.1515/rns.2011.061 · Cited by 164
“The blocking of insulin receptors prevents the activation of PI3K, and subsequently that of Akt [which phosphorylates GSK3 α (Ser21) or GSK3 β (Ser9)].”
BackgroundInfluentialTchantchou, F., Lacor, P. N., Cao, Z., Lao, L., Hou, Y., Cui, C., Klein, W. L., & Luo, Y. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1189 · Cited by 162
“ADDL has been recently reported to inhibit insulin receptors and multiple downstream kinases that are necessary for hippocampal LTP [23,31] and some are upstream regulators of CREB.”
BackgroundHamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 158
“Indeed, since the insulin [180] and Wnt [220] signaling pathways are targeted by Aβ peptide toxicity, amyloid accumulation also contributes to an increased activation of GSK3β, and consequently leads to tau hyperphosphorylation, thus establishing a link between senile plaques and NFTs in AD [158,213].”
BackgroundInsulin resistance and pathological brain ageing
Cholerton, B., Baker, L. D., & Craft, S. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03464.x · Cited by 160
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
Beeri, M. S., Schmeidler, J., Silverman, J. M., Gandy, S., Wysocki, M., Hannigan, C. M., Purohit, D. P., Lesser, G., Grossman, H. T., & Haroutunian, V. (2008) · Neurology · doi:10.1212/01.wnl.0000324925.95210.6d · Cited by 157
Roles of O-GlcNAc in chronic diseases of aging
Banerjee, P. S., Lagerlöf, O., & Hart, G. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.05.005 · Cited by 174
Insulin and Alzheimer's Disease: Untangling the Web
Craft, S., Cholerton, B., & Baker, L. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129042 · Cited by 155
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 155
“The involvement of mGluR5 also suggests a mechanism for how oligomers affect LTP/LTD and calcium homeostasis, especially given that mGluR5 antagonists prevent these cellular responses to oligomer treatment (Renner et al. 2010; Shankar et al. 2008; Townsend et al. 2007; Wang et al. 2004).”
Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O’Halloran, D., Hölscher, C., & O’Neill, C. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8199-5 · Cited by 168
“…pathological binding of Ab oligomers to dendritic spines in vitro (De Felice et al. 2009), and functioning IR receptors will increase Ab clearance, reduce levels of extracellular Ab oligomers and can impact positively on measures of cognitive function (Townsend et al. 2007; Zhao et al. 2008, 2009).”
Devi, L., Alldred, M. J., Ginsberg, S. D., & Ohno, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032792 · Cited by 155
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Amyloid β oligomers (AβOs) in Alzheimer’s disease
Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 160
Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease
O'Neill, C., Kiely, A. P., Coakley, M. F., Manning, S., & Long-Smith, C. M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120080 · Cited by 139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
Berlanga-Acosta, J., Guillén-Nieto, G., Rodríguez-Rodríguez, N., Bringas-Vega, M. L., García-del-Barco-Herrera, D., Berlanga-Saez, J. O., García-Ojalvo, A., Valdés-Sosa, M. J., & Valdés-Sosa, P. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560375 · Cited by 136
Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity
Antion, M. D., Merhav, M., Hoeffer, C. A., Reis, G., Kozma, S. C., Thomas, G., Schuman, E. M., Rosenblum, K., & Klann, E. (2008) · Learning & Memory · doi:10.1101/lm.661908 · Cited by 138
“This observation is further supported by the finding that inhibitors of the insulin receptor family signaling pathway produce dramatic reductions in PI3K–Akt activity that is associated with impaired L-LTP (Townsend et al. 2007).”
Site-Specific Blockade of RAGE-VdPrevents Amyloid-β Oligomer Neurotoxicity
Sturchler, E., Galichet, A., Weibel, M., Leclerc, E., & Heizmann, C. W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4878-07.2008 · Cited by 136
“Furthermore, it has been suggested that defects in both ERK and JNK signaling underlie neuronal dysfunction such as caspase activation evoked by A oligomers in various AD paradigms (Bell et al., 2004; Chong et al., 2006; Ma et al., 2007; Townsend et al., 2007; Yan and Wang, 2007).”
BackgroundInfluentialDoi, Y., Mizuno, T., Maki, Y., Jin, S., Mizoguchi, H., Ikeyama, M., Doi, M., Michikawa, M., Takeuchi, H., & Suzumura, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090418 · Cited by 135
“In addition, oA interferes with insulin receptor function in hippocampal neurons and inhibits the activation of specific kinases required for long-term potentiation.(35) In the present study, we have confirmed that oA 1-42 exhibits more potent neurotoxicity than fA 1-42 in murine cortical cultures.”
BackgroundMolecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease
Ma, T., & Klann, E. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07506.x · Cited by 132
“Ab was shown to impair insulin-PI3K-Akt signaling (Magrané et al. 2005; Townsend et al. 2007; De Felice et al. 2009; Lee et al. 2009) and insulin treatment was reported to improve cognitive function in patients with early AD (Reger et al. 2008).”
BackgroundYang, T., Knowles, J. K., Lu, Q., Zhang, H., Arancio, O., Moore, L. A., Chang, T., Wang, Q., Andreasson, K., Rajadas, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003604 · Cited by 130
“and Aβ contribute to AD, preventing those interactions could inhibit neurodegeneration. Further, modulating the receptor to reduce activation of c-Jun and calpain activity could counteract Aβ activation of these signaling intermediates. Moreover, since Aβ down-regulates trophic signaling, particularly the PI3K/AKT pat…”
BackgroundInteractions Between Age, Stress and Insulin on Cognition: Implications for Alzheimer's Disease
Solas, M., Aisa, B., Mugueta, M. C., Del Río, J., Tordera, R. M., & Ramírez, M. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.13 · Cited by 124
The case for soluble Aβ oligomers as a drug target in Alzheimer's disease
Hefti, F. F., Goure, W. F., Jerecìć, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.002 · Cited by 138
Tau Phosphorylation by GSK3 in Different Conditions
Avila, J., León-Espinosa, G., García, E., García-Escudero, V., Hernández, F., & DeFelipe, J. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/578373 · Cited by 117
“It is also known that the accumulation of betaamyloid peptide facilitates tau phosphorylation by GSK3 through the interference with insulin or wnt pathways [16, 17].”
BackgroundTokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348300 · Cited by 117
Amyloid β and APP as biomarkers for Alzheimer’s disease
Zetterberg, H., Blennow, K., & Hanse, E. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.08.002 · Cited by 139
“Further, insulin can antagonize the LTP-inhibiting effect of A (Lee et al., 2009; Townsend et al., 2007).”
BackgroundGrillo, S. L., Duggett, N. A., Ennaceur, A., & Chazot, P. L. (2013) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2013.02.015 · Cited by 120
“tion of GSK-3b via inhibiting the wnt or insulin pathways, where GSK-3b then phosphorylates tau [28,29].”
BackgroundShi, L., Zhang, Z., Li, L., & Hölscher, C. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.032 · Cited by 123
“Importantly, brain insulin de-sensitization correlates well with cognitive decline [15, 55] and with tau protein phosphorylation levels [56], and the application of insulin via nasal spray showed good improvements in AD patients [57, 58].”
BackgroundTau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits
de Barreda, E. G., Pérez, M., Ramos, P. G., de Cristobal, J., Martín-Maestro, P., Morán, A., Dawson, H. N., Vitek, M. P., Lucas, J. J., Hernández, F., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.017 · Cited by 112
“In both cases, this results in an increase of GSK3β activity (Busciglio et al., 1995, Ferreira et al., 1997, Takashima et al., 1998, Townsend et al., 2007, Magdesian et al., 2008).”
APP Receptor? To Be or Not To Be
Deyts, C., Thinakaran, G., & Parent, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.005 · Cited by 112
“IGF/insulin receptor sAPP/, Ab PI3K/PKB/Akt/GSK3, Erk/MAPK, CaMKII [156,162,193]”
BackgroundInfluentialThe Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease
Wang, Z.-X., Tan, L., Liu, J., & Yu, J.-T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9143-0 · Cited by 110
Fuentealba, R. A., Liu, Q., Kanekiyo, T., Zhang, J., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021030 · Cited by 97
Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum
Ríos, J. A., Cisternas, P., Arrese, M. A., Salesa Barja, Y., & Inestrosa, N. C. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.07.004 · Cited by 110
“results indicate that insulin could play an important role in regulating tau protein, Ab and APP metabolism in neurons (Townsend et al., 2007).”
BackgroundHow Can Insulin Resistance Cause Alzheimer’s Disease?
Yoon, J. H., Hwang, J., Son, S. U., Choi, J., You, S.-W., Park, H., Cha, S.-Y., & Maeng, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043506 · Cited by 116
Hanson, A. J., Bayer-Carter, J. L., Green, P. S., Montine, T. J., Wilkinson, C. W., Baker, L. D., Watson, G. S., Bonner, L. M., Callaghan, M., Leverenz, J. B., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.396 · Cited by 102
Li, Y., Yang, J., Liu, H., Yang, J., Du, L., Feng, H., Tian, Y., Cao, J., & Ran, C. (2017) · Chemical Science · doi:10.1039/c7sc02050c · Cited by 106
Faucher, P., Mons, N., Micheau, J., Louis, C., & Beracochea, D. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00245 · Cited by 100
“However, the direction of ERK regulation by Aβ is far to end up with a clear consensus, all sorts of ERK responses to Aβ being reported (Stanciu et al., 2000; Dineley et al., 2001; Savage et al., 2002; Townsend et al., 2007; Frasca et al., 2008).”
BackgroundSilva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99
“If Akt is not phosphorylated, GSK3-b remains active [93] and is described as responsible for events related to AD pathology, including the hyperphosphorylation of Tau [94].”
BackgroundThe effects of cardiovascular risk factors on cognitive compromise
Beeri, M. S., Ravona-Springer, R., Silverman, J. M., & Haroutunian, V. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/msbeeri · Cited by 99
“Aβ, the main component of neuritic plaques, hallmark lesions of AD, decreases insulin affinity and reduces the binding of insulin to its receptor(48) preventing rapid activation of specific kinases required for multiple cellular functions, including longterm potentiation (LTP).(49) Soluble Aβ oligomers were recently s…”
Synaptic plasticity in Alzheimer’s disease and healthy aging
Cuestas Torres, D. M., & Cardenas, F. P. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0058 · Cited by 98
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“What is more, restoring LTP impaired by AβOs is possible by using a selective neuronal nicotinic receptor partial agonist SSR180711, which completely rescued both early and late LTP impaired by Aβ42 oligomers [154].”
BackgroundInfluentialAmyloid-β Induces Hepatic Insulin Resistance by Activating JAK2/STAT3/SOCS-1 Signaling Pathway
Zhang, Y., Zhou, B., Zhang, F., Wu, J., Hu, Y., Liu, Y., & Zhai, Q. (2012) · Diabetes · doi:10.2337/db11-0499 · Cited by 92
“Ab competitively binds to InsR, interferes with its autophosphorylation, and prevents the activation of downstream kinases required for long-term potentiation in hippocampal neurons (7,10).”
Metadata
- Authors
- Townsend, M., Mehta, T., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Selkoe, Dennis J.
- ORCID
- Selkoe, Dennis J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 282
- Issue
- 46
- Pages
- 33305-33312
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2058581619
- Cited by
- 318
- References
- 55
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 15 · 2021: 6 · 2020: 13 · 2019: 9 · 2018: 12 · 2017: 14 · 2016: 26 · 2015: 19 · 2014: 22 · 2013: 26 · 2012: 40
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4724 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (AG027443, R01AG027443)
- National Institute of Neurological Disorders and Stroke (T32 NS07484-04, T32NS007484)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, insulin receptor, signal transduction, long-term potentiation, ERK MAPK, CaMKII, Akt/protein kinase B, phosphatidylinositol 3-kinase, protein kinase A, protein kinase C, kinase autophosphorylation, hippocampal neurons, Alzheimer's disease, amyloid hypothesis, synaptic plasticity
- MeSH terms
- Animals, Cricetulus, Electrophysiology, Enzyme Activation, Cricetinae, Hippocampus, Humans, Insulin, Models, Biological, Phosphorylation, Receptor, Insulin, Signal Transduction, Amyloid beta-Peptides, CHO Cells, Long-Term Potentiation, Phosphatidylinositol 3-Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.